Vyepti® (epitinezumab)

POWERFUL PREVENTIVE MIGRAINE TREATMENT[1–3*]

* Significant reduction in monthly migraine days (MMDs; Weeks 1–12) vs placebo in chronic migraine ($p<0.0001$) and episodic migraine ($p<0.05$), and migraine-related disability vs placebo in chronic migraine (HIT-6, Weeks 1–12, $p<0.05$)[1–3]

vyepti® (eptinezumab)

Powerful IV migraine preventive treatment[1-3*]

* Significant reduction in monthly migraine days (MMDs; Weeks 1–12) vs placebo in chronic migraine (p<0.0001) and episodic migraine (p<0.05), and migraine-related disability vs placebo in chronic migraine (HIT-6, Weeks 1–12, p<0.05)[1–3]

Efficacy from day one in chronic migraine[1,2,4†]

† Percentage patients with migraine on day one post-infusion vs placebo in chronic migraine (p<0.0001).[1]

Sustained preventive treatment of migraine for 12 weeks from a single dose[1,4‡]

‡ Reduction in monthly migraine days vs placebo for all intervals from day one alone to days 1–84 (p<0.05), post-hoc analysis.[1]

Significant reduction in MMDs in patients with medication overuse headache (MOH)[1,2§]

§ Weeks 1–12 vs placebo (p<0.0001), post-hoc analysis in patients with chronic migraine and MOH.[1,5]

The first intravenous anti-CGRP monoclonal migraine treatment available in Australia[1]

30 min IV infusion[1]

Every 12 weeks (3 months)[1]

100 mg dose recommended[1]

Scan the QR code to learn more about Vyepti dosing and infusion

Visit **Progress in Mind – The Psychiatry & Neurology Resource Centre** at **https://australia.progress.im/en** to access the latest news, resources and insights within your field

Vyepti® PBS Information:
This product is not listed on the PBS.

Vyepti is indicated for the preventive treatment of migraine in adults.[1]

Please review the full Approved Product Information for Vyepti before prescribing, available by calling Lundbeck on 1300 721 277.

Minimum Product Information: Vyepti® (eptinezumab). **Indications:** Vyepti is indicated for the preventive treatment of migraine in adults. **Contraindications:** Hypersensitivity to eptinezumab or any of the excipients. **Precautions:** Serious hypersensitivity reactions, including anaphylactic reactions may occur within minutes of the infusion. **Adverse Effects:** The common adverse events are nasopharyngitis and hypersensitivity. Most hypersensitivity reactions occurred during the infusion and were not serious; angioedema, urticaria, facial flushing and rash have been reported. Infusion-site related reactions occurred infrequently. **Dosage & Administration:** The recommended dose is 100 mg administered by intravenous infusion every 12 weeks and initiated and supervised by a healthcare professional. Vyepti 100 mg/mL is available as a single-dose vial. Treatment benefit should be assessed 3–6 months after initiation of treatment. Administration: Vyepti is for intravenous infusion only after dilution. Infusion takes place over approximately 30 minutes. For preparation and infusion instructions consult Approved PI. No dosage adjustments are recommended for age, gender or race. No dedicated hepatic and renal impairment studies were conducted; however, population pharmacokinetic analysis revealed no differences that would require dose adjustments. Insufficient data are available for use in elderly, children or adolescents. **Black triangle scheme:** This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at https://www.tga.gov.au/reporting-problems. **Date of Minimum PI:** 17 June 2021

References: 1. Vyepti® Approved Australian Product Information. 2. Ashina M *et al. Cephalalgia* 2020; 40:241–54. 3. Lipton RB *et al. Neurology* 2020; 94e1365–77. 4. Dodick DW *et al. Headache* 2020; 60:2220–31. 5. Diener H-C *et al. Headache*. 2021; 61:125–36.

HIT-6, 6-item Headache Impact Test; MMD, monthly migraine days.

vyepti® (eptinezumab)

Lundbeck